Plandaí Biotechnology's VP of Global Marketing Jamen Shively Discusses Future of Cannabis at the Company
May 13 2014 - 9:00AM
Marketwired
Plandaí Biotechnology's VP of Global Marketing Jamen Shively
Discusses Future of Cannabis at the Company
NEW YORK, NY--(Marketwired - May 13, 2014) - Plandaí
Biotechnology (OTCQB: PLPL) has plans to develop and market a
cannabis extract once the political climate in the US sorts itself
out. Nationwide legalization seems to be just a matter of
time, and there are a host of companies, including Plandaí, that
are laying the framework for a successful future in the cannabis
space well ahead of legalization. One such move was naming
marijuana entrepreneur and former Microsoft executive Jamen Shively
to its Board of Directors and announcing him as its Vice President
of Global Marketing.
With less than 6 months until mid-term elections where it's
likely even more states will legalize marijuana for, at minimum,
medicinal purposes, Stock Market Media Group (SMMG) spoke with
Jamen Shively (JS) to discuss Plandaí's future in the cannabis
arena.
SMMG: Moving forward what are Plandaí's objectives regarding
cannabis?
JS: "We have two short-term objectives with respect to
cannabis. First, we need a legal platform from which we can
conduct our research, and secondly, we need to finalize our
Phytofare™ Pheroid® cannabinoid complex."
SMMG: Tell us more about finding a legal platform?
JS: "Regardless of state law, marijuana use -- even for medical
research, is not legal on the federal level. While the FDA has
granted some companies a limited license to perform trials, this is
a long and arduous path.
So, our first goal is to find a government that is supportive of
medical marijuana research. As you've read, we're in active
discussions with South Africa as well as other countries we haven't
disclosed. I'm confident that we will soon have the green
light from somewhere."
SMMG: Explain finalizing the Phytofare™ Pheroid® cannabinoid
complex?
JS: "We believe, based on scientific evidence, that we can
retain the acid forms of THC, THCA and THCB in their natural state,
thus negating the psychotomimetic actions of cannabis.
Pheroid's role is to provide protection to the nanoparticle
antioxidants during the digestive process and through the liver,
allowing the undamaged antioxidant molecules to pass unmetabolized
into the bloodstream.
Once in the bloodstream, human cells perceive the fatty acids as
a food source and bring the nanoparticles inside the cell membrane
where, through the process of glycolysis, the Pheroid is eaten
away, releasing cannabinoids into the white blood cells.
The white blood cells should then naturally travel along
pathways and pass through the Blood Brain Barrier, delivering a
clinical dose of Phtofare Cannabis complex able to undertake
efficient antagonistic scavenging of free radicals, to the brain
CB1 and CB2 neuron receptors."
SMMG: So the goal is a pharmaceutical?
JS: "Without boring you with too much science, we should be able
to retain THCA and THCB without converting to the psychoactive
THC. Our goal is to produce a non-psychoactive cannabinoid
extract pharmaceutical, which should take cannabis extracts out of
the banned substance category, thus creating a new class of
botanical drugs containing cannabis through the supporting research
and development of our product.
Long term, we hope to eventually receive an FDA clearance for
our Phytofare™ Pheroid® Cannabis complex for treating one or more
illnesses."
SMMG: Does this mean no Plandaí cannabis extracts hitting the
shelves anytime soon?
JS: "Not yet. First the research, then the product. We
could rush something to market and slap the Diego Pellicer name on
it, but we'd be no different than everyone else out there selling
something with no regulations, no standards, and no hard clinical
data.
This is not a short-term view we're taking -- we believe that
cannabis has the potential to be an amazing wellness product, but
first we have legal hurdles to overcome and then a lot of
research."
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a
platform for corporate stories to unfold in the media with Reports,
Interviews and Articles. SMMG is compensated for Plandaí content by
a third party who reserves the right to buy, sell or remain neutral
on securities after the publication of this article. SMMG has
received total compensation of $46,115, for content related to
Plandaí. For more information:
www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Apr 2024 to May 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From May 2023 to May 2024